Lauren Sciences to Develop V-Smart Therapeutics for ALS

Lauren Sciences LLC, a New York based biotechnology company, announced the award of a grant from the ALS Association (ALSA) to its collaborating research team at Ben Gurion University (see April 2012 news story) to develop the V-Smart technology for therapeutic applications in ALS. The technology is based on blood-brain-barrier (BBB) permeable nanovesicles that encapsulate small molecules, nucleic acids or proteins, and deliver them to the brain in a controlled manner. The ALSA funding is aimed at developing this platform to deliver neurotrophic factors, which would otherwise not cross the BBB, to degenerating motor neurons in the brain. Preclinical studies using this approach in Parkinson’s disease have demonstrated beneficial effects.

Lauren Sciences LLC, a New York based biotechnology company, announced the award of a grant from the ALS Association (ALSA) to its collaborating research team at Ben Gurion University (see April 2012 news story) to develop the V-Smart technology for therapeutic applications in ALS. The technology is based on blood-brain-barrier (BBB) permeable nanovesicles that encapsulate small molecules, nucleic acids or proteins, and deliver them to the brain in a controlled manner. The ALSA funding is aimed at developing this platform to deliver neurotrophic factors, which would otherwise not cross the BBB, to degenerating motor neurons in the brain. Preclinical studies using this approach in Parkinson’s disease have demonstrated beneficial effects.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail